drug

sugammadex sodium

Marketedupdated 2mo ago

by B. Braun Medical Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 50m ago

Found something off?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 27, 2026

20 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jul 27, 2026patentUS RE44733*PED20d
Jul 27, 2026patentUS RE44733*PED20d
Jan 27, 2026compositionUS RE44733
Jan 27, 2026compositionUS RE44733

FDA exclusivities (4)

Jun 12, 2028PEDPediatric (6mo bonus)1.9y
Jun 12, 2028PEDPediatric (6mo bonus)1.9y
Dec 12, 2027NPPNew Product (3y)1.4y
Dec 12, 2027NPPNew Product (3y)1.4y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying sugammadex sodium

phase4Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complicationscompletedn=120
phase1Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation With Moderate vs. Deep Neuromuscular Blockterminatedn=12